Meyer Burger Technology has successfully issued green senior unsecured guaranteed convertible bonds due 2029 in the aggregate amount of EUR 216.3 m. The bonds were placed in a private placement with a coupon of 3.75% per annum. The
Tags :Slider
Renowned legal powerhouses Allen & Overy and Shearman & Sterling have unveiled their plans to merge, establishing an unprecedented global law firm known as Allen Overy Shearman Sterling – or A&O Shearman for short.
Banking & Finance
Corporate
Tech
Homburger: wefox revolving credit facility and a Series D extension
Wefox the Berlin-based insurtech company, has secured a EUR 50 m revolving credit facility arranged by J.P. Morgan Securities and Barclays Bank, following a USD 55 m second close in its Series D that was completed
ANYbotics, a renowned maker of four-legged robots, announced the closing of its CHF 45 million series B financing round. The financing round was led by Walden Catalyst Ventures and included the participation of the co-investors NGP
Homburger advised the initial purchasers and arrangers in connection with CABB group’s EUR 250 million senior secured floating rate notes and EUR 420 million 8.75% senior secured fixed rate notes due 2028 and a new EUR 110 million revolving
Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a pioneering and unique solution for ecological and sustainable investments in gold. The company has issued and listed a new exchange traded product (ETP) on
NKF advised Ecorobotix as Swiss counsel on its CHF 46 million Series B Prime financing round led by AQTON Private Equity and Cibus Capital. Additional investments came from Swisscanto Invest/Swisscanto Growth Fund I, Yara Growth
Siegfried and DiNAQOR entered into an agreement relating to the acquisition by Siegfried of a 95% stake in DiNAQOR DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and
Emergent BioSolutions, the New York Stock Exchange listed developer and manufacturer of vaccines, completed the sale of its travel vaccine business to Bavarian Nordic for an upfront payment of USD 270 million. At closing Emergent received
NewBiologix, a technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies, raised USD 50 million in series A financing. The round was led by Recipharm (an EQT
